SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.98 HKD | 0.00% |
|
-0.33% | +29.17% |
| Apr. 18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
| Apr. 01 | SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 49% by 2025.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.6 for the current year and 10.16 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.17% | 1.4B | - | ||
| -2.86% | 87.31B | A- | ||
| +3.95% | 40.86B | A- | ||
| -21.94% | 29.36B | B- | ||
| +55.83% | 24.49B | A | ||
| -5.41% | 17.31B | C | ||
| -44.23% | 11.26B | B | ||
| -17.60% | 11.62B | B- | ||
| -13.96% | 11.31B | D+ | ||
| +6.67% | 8.31B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6600 Stock
- Ratings SciClone Pharmaceuticals (Holdings) Limited
